A phase II study of BEZ235 in patients with everolimusresistant, advanced pancreatic neuroendocrine tumours

Anticancer Research

Volumn 36, Issue 2, 2016, Pages 713-720

  Fazio, Nicola ^a   Buzzoni, Roberto ^b   Baudin, Eric ^c   Antonuzzo, Lorenzo ^d   Hubner, Richard A ^e   Lahner, Harald ^f   De Herder, Wouter W ^g   Raderer, Markus ^h   Teulé, Alexandre ⁱ   Capdevila, Jaume ^j   Libutti, Steven K ^k   Kulke, Matthew H ^l   Shah, Manisha ^m   Dey, Debarshi ⁿ   Turri, Sabine ^o   Aimone, Paola ^o   Massacesi, Cristian ^p   Verslype, Chris ^q  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d CAREGGI UNIVERSITY HOSPITAL   (Italy)

^e CHRISTIE HOSPITAL   (United Kingdom)

^f UNIVERSITY OF DUISBURG ESSEN   (Germany)

^g ERASMUS MEDICAL CENTER   (Netherlands)

^h MEDICAL UNIVERSITY OF VIENNA   (Austria)

ⁱ CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^j VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^k ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^l DANA FARBER CANCER INSTITUTE   (United States)

^m OHIO STATE UNIVERSITY   (United States)

ⁿ Novartis Healthcare Private Limited   (India)

^o NOVARTIS PHARMA AG   (Switzerland)

^p Novartis Oncology ^*  (France)

^q UNIVERSITY HOSPITALS LEUVEN   (Belgium)

more..

Author keywords

BEZ235; Everolimus; MTOR; PI3K; PNETs

Indexed keywords

DACTOLISIB; EVEROLIMUS; GAMMA GLUTAMYLTRANSFERASE; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; MTOR PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE INHIBITOR; QUINOLINE DERIVATIVE; TARGET OF RAPAMYCIN KINASE;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; CANCER PATIENT; CHOLESTASIS; CLINICAL ARTICLE; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ERYSIPELAS; FATIGUE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEART ARREST; HUMAN; HYPERGLYCEMIA; HYPERKINESIA; HYPERTRANSAMINASEMIA; HYPONATREMIA; INFECTION; LIVER PAIN; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; NAUSEA; OPEN STUDY; PANCREATIC NEUROENDOCRINE TUMOR; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SEPSIS; STOMATITIS; SYSTOLIC DYSFUNCTION; UPPER ABDOMINAL PAIN; VERY ELDERLY; VOMITING; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG RESISTANCE; ENZYMOLOGY; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NEUROENDOCRINE TUMORS; ORAL DRUG ADMINISTRATION; PANCREATIC NEOPLASMS; PATHOLOGY; PROSPECTIVE STUDY; TIME FACTOR; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; EVEROLIMUS; FEMALE; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASE; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; QUINOLINES; TIME FACTORS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84961831124     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Halfdanarson TR, Rabe KG, Rubin J and Petersen GM: Pancreatic neuroendocrine tumors (PNETs): Incidence, prognosis and recent trend toward improved survival. Ann Oncol 19: 1727-1733, 2008.
2. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A and Evans DB: One hundred years after "carcinoid": Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26: 3063-3072, 2008.
3. Lepage C, Bouvier AM, Phelip JM, Hatem C, Vernet C and Faivre J: Incidence and management of malignant digestive endocrine tumours in a well-defined French population. Gut 53: 549-553, 2004.
4. Sadaria MR, Hruban RH and Edil BH: Advancements in pancreatic neuroendocrine tumors. Expert Rev Gastroenterol Hepatol 7: 477-490, 2013.
5. Missiaglia E, Dalai I, Barbi S, Beghelli S, Falconi M, della Peruta M, Piemonti L, Capurso G, Di Florio A, delle Fave G, Pederzoli P, Croce CM and Scarpa A: Pancreatic endocrine tumors: Expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol 28: 245-255, 2010.
6. Yao JC, Phan AT, Jehl V, Shah G and Meric-Bernstam F: Everolimus in advanced pancreatic neuroendocrine tumors: The clinical experience. Cancer Res 73: 1449-1453, 2013.
7. Afinitor Prescribing Information. 2012: Http://www.accessdata. fda.gov/drugsatfda-docs/label/2012/022334s017lbl.pdf.
8. Afinitor Summary of Product Characteristics. 2014: Http://www.medicines.org.uk/emc/medicine/22281/spc.
9. Tijeras-Raballand A, Neuzillet C, Couvelard A, Serova M, de Gramont A, Hammel P, Raymond E and Faivre S: Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): Molecular basis, preclinical data, and counteracting strategies. Target Oncol 7: 173-181, 2012.
10. Delbaldo C, Faivre S, Dreyer C and Raymond E: Sunitinib in advanced pancreatic neuroendocrine tumors: Latest evidence and clinical potential. Ther Adv Med Oncol 4: 9-18, 2012.
11. Caplin ME, Pavel M, Cwikla JB, Phan AT, Raderer M, Sedlackova E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Blumberg J and Ruszniewski P; CLARINET Investigators: Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 371: 224-233, 2014.
12. Fonseca PJ, Uriol E, Galvan JA, Alvarez C, Perez Q, Villanueva N, Berros JP, Izquierdo M and Vieitez JM: Prolonged clinical benefit of everolimus therapy in the management of high-grade pancreatic neuroendocrine carcinoma. Case Rep Oncol 6: 441-449, 2013.
13. Wolin EM: PI3K/AKT/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors. Cancer Lett 335: 1-8, 2013.
14. Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, Martinelli E, Ramon y Cajal S, Jones S, Vidal L, Shand N, Macarulla T, Ramos FJ, Dimitrijevic S, Zoellner U, Tang P, Stumm M, Lane HA, Lebwohl D and Baselga J: Dose- And schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: A phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 26: 1603-1610, 2008.
15. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W and Garcia-Echeverria C: Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 7: 1851-1863, 2008.
16. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D and Verweij J: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247, 2009.
17. NCI Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Quick Reference. 2014: Http://evs.nci.nih. gov/ftp1/CTCAE/About.html.
18. Rodon J, Burris HA, Schellens JHM, Schuler M, Goodman O, Britten C, Richards D, Demanse D, Silva A and Baselga J: Phase I dose-escalation of the oral dual mTOR/PI3K inhibitor BEZ235, solid dispersion system (SDS) sachet formulation, in patients with advanced solid tumors. EORTC-NCI-AACR Abstract 366, 2012.
19. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D and Oberg K: RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group: Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364: 514-523, 2011.
20. Arkenau H, Jones S, Kurkjian C, Infante JR, Pant S, Burris HA, Moore K, McMeekin S, Greco FA, Ramsey SD and Bendell JC: The PI3K/mTOR inhibitor BEZ235 given twice daily for the treatment of patients (pts) with advanced solid tumors. J Clin Oncol 30: Abstract 3097, 2012.
21. Kaplan B, Qazi Y and Wellen JR: Strategies for the management of adverse events associated with mTOR inhibitors. Transplant Rev (Orlando) 28: 126-133, 2014.
22. Busaidy NL, Farooki A, Dowlati A, Perentesis JP, Dancey JE, Doyle LA, Brell JM and Siu LL: Management of metabolic effects associated with anticancer agents targeting the PI3K-AktmTOR pathway. J Clin Oncol 30: 2919-2928, 2012.
23. Rodon J, Brana I, Siu LL, De Jonge MJ, Homji N, Mills D, Di Tomaso E, Sarr C, Trandafir L, Massacesi C, Eskens F and Bendell JC: Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. Invest New Drugs 32: 670-681, 2014.
24. Rodon J, Dienstmann R, Serra V and Tabernero J: Development of PI3K inhibitors: Lessons learned from early clinical trials. Nat Rev Clin Oncol 10: 143-153, 2013.
25. Shapiro GI, Rodon J, Bedell C, Kwak EL, Baselga J, Brana I, Pandya SS, Scheffold C, Laird AD, Nguyen LT, Xu Y, Egile C and Edelman G: Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral panclass I PI3K inhibitor, in patients with advanced solid tumors. Clin Cancer Res 20: 233-245, 2014.
26. Mahadevan D, Chiorean EG, Harris WB, Von Hoff DD, Stejskal- Barnett A, Qi W, Anthony SP, Younger AE, Rensvold DM, Cordova F, Shelton CF, Becker MD, Garlich JR, Durden DL and Ramanathan RK: Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies. Eur J Cancer 48: 3319-3327, 2012.
27. Hong DS, Bowles DW, Falchook GS, Messersmith WA, George GC, O'Bryant CL, Vo AC, Klucher K, Herbst RS, Eckhardt SG, Peterson S, Hausman DF, Kurzrock R and Jimeno A: A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 18: 4173-4182, 2012.
28. Markman B, Tabernero J, Krop I, Shapiro GI, Siu L, Chen LC, Mita M, Melendez Cuero M, Stutvoet S, Birle D, Anak O, Hackl W and Baselga J: Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol- 3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. Ann Oncol 23: 2399-2408, 2012.